Pursuing Breakthrough Solutions
for Devastating Neurological Diseases

Your brain is a universe, PurMinds is pioneering the exploration of this intriguing frontier.

COMPANY HIGHLIGHTS

PurMinds is a trailblazer, pursuing breakthrough solutions for devastating neurological diseases while setting the gold standards for research, development, and proven scientific methods to serve the psychedelic science community.

We champion accelerated research and development through a robust psychedelic strategy, utilizing advanced development pathways in our flagship neuroscience lab and compound production facility in Ontario, as well as our partner’s R&D facilities in Israel.

A disturbingly high prevalence of anxiety and depression around the world has compelled medical researchers to develop novel treatments.

No meaningful progress has been made in treating progressive and irreversible neurodegeneration in 50 years.

0 %
OF PATIENTS RELAPSE AFTER
CONVENTIONAL TREATMENTS
$ 0 B/year
INDIRECT ECONOMIC COSTS OF MENTAL DISORDERS in AMERICA
$ 0 B
GLOBAL MARKET FOR
ANXIETY & DEPRESSION by 2027
0 M
NEW CASES OF DEMENTIA
EACH YEAR
$ 0 B/year
GLOBAL SOCIETAL COST
OF DEMENTIA
$ 0 B
MARKET VALUE FOR
DEMENTA DRUGS by 2027

Psychedelics inspired breakthrough therapies are a shining beacon of hope for progressive neurologic diseases hallmarked by neurodegeneration.

Our Integrative Business Pillars

Neuroscience & Drug Development ​

Compound Supply & Standardization

Analytical Chemistry & Data Science

Strategic investment and partnership for enhanced targeted drug delivery

Through our partnership with Nextage Therapeutics (NXTG: TASE), PurMinds has access to a patented liposomal drug delivery system, which enables drugs to penetrate the Blood-Brain-Barrier (BBB). This allows for the delivery of significantly lower doses, while exhibiting negligible dissipation to areas outside the brain, protecting from unwanted side effects commonly associated with psychedelic compounds.

WHY CHOOSE US

ACCELERATED DRUG DISCOVERY ENGINE

● Industry differentiating neuronal screening technology 
● In-vitro screening coupled with AI data engine

NON-DILUTIVE MODEL​

Hybrid model of wholly-owned pipeline of drug and API candidates plus partnerships with pharma and biotech

BEST-IN-CLASS ASSETS

● 8+ Therapeutic candidate programs 
● 2 molecules with Blood Brain Barrier Targeting Technologies – industry benchmark for delivery systems
● Robust patent strategy

FOCUSED THERAPEUTIC DISCOVERY THESIS

● Dementia:  Alzheimer’s Disease, Vascular Dementia (stroke), ALS, Parkinson’s
● Major Depressive Disorder  Anxiety and Depression

INDUSTRY LEADING SUPPLIER

● cGMP, Standardized sources of psychedelic compounds & formulations (natural and synthetic)
● Cross continental cGMP R&D and Manufacturing in Canada and Israel

EXPERIENCED MANAGEMENT

● Risk-averse, conservative, experienced leadership team
● 50+ combined scientific team with 100+ years of experience

PurMinds Logo

PurMinds’ collective expertise at executing an accelerated development strategy through all phases of drug development and commercialization will advance our global development programs and expand our drug and API candidate pipeline.
Contact us for an investor presentation or partnership opportunities, click Contact Us or email us at info@purminds.com

Let’s Get In Touch!

We love to hear from you. Drop us a line, or give us a heads up if you’re interested in visiting us.

Contact Us
First
Last
Your Business Title in the Company
Infomation You Want to Receive